Targeting EGFR-overexpressed A431 cells with EGF-labeled silica-coated magnetic nanoparticles
Source abstract
Abstract
Human epidermal growth-factor receptor (EGFR) has emerged as an attractive target for cancer therapy. In this study, amino- or carboxyl-functionalized silica-coated maghemite nanoparticles were conjugated with epidermal growth-factor (EGF) using five different binding modes: carbodiimide chemistry, two types of homo-bifunctional cross-linking reagents, and electrostatic interactions between the nanoparticles and the EGF. The nanoparticles and their aqueous suspensions were characterized by transmission electron microscopy, zeta-potential measurements and dynamic light scattering. The binding efficiency of the EGF to the nanoparticles was measured by flow cytometry using a specific anti-EGF antibody. The ability of EGF bioconjugates to target the EGF receptors was tested using EGFR over-expressing A431 cells in comparison to EGFR negative HeLa cells. Our results showed that the bioconjugates where the EGF was bonded by carbodiimide chemistry are the most effective for the specific targeting of EGFR-expressing cells in vitro.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Monoclonal and Polyclonal Antibodies Research · Glycosylation and Glycoproteins Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Artemov D, Mori N, Ravi R, Bhujwalla ZM (2003) Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 63:2723–2727. doi: 10.1002/mrm.10406
2. Bachran D, Schneider S, Bachran C, Urban R, Weng A, Melzig MF, Hoffmann C, Kaufmann AM, Fuchs H (2010) Epidermal growth factor receptor expression affects the efficacy of the combined application of saponin and a targeted toxin on human cervical carcinoma cells. Int J Cancer 127:1453–1461. doi: 10.1002/ijc.2512310.1002/ijc.25123 ↗
3. Banarjee SS, Chen D-H (2009) Cyclodextrin-conjugated nanocarrier for magnetically guided delivery of hydrophobic drugs. J Nanopart Res 11:2071–2078. doi: 10.1007/s11051-008-9572-z10.1007/s11051-008-9572-z ↗
4. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626. doi: 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
5. Čampelj S, Makovec D, Drofenik M (2008) Preparation and properties of water-based magnetic fluids. J Phys Condens Mater 20:204101. doi: 10.1088/0953-8984/20/20/20410110.1088/0953-8984/20/20/204101 ↗
6. Chen H, Yeh J, Wang L, Khurshid H, Peng N, Wang AY, Mao H (2010) Preparation and control of the formation of single core and clustered nanoparticles for biomedical applications using a versatile amphiphilic diblock copolymer. Nano Res 3:852–862. doi: 10.1007/s12274-010-0056-y10.1007/s12274-010-0056-y ↗
7. Cho YS, Yoon TJ, Jang ES, Hong KS, Lee SY, Kim OR, Park C, Kim YJ, Yi GC, Chang K (2010) Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett 299:63–71. doi: 10.1016/j.canlet.2010.08.00410.1016/j.canlet.2010.08.004 ↗
8. Creixell M, Herrera AP, Ayala V, Latorre-Esteves M, Perez-Torres M, Torres-Lugo M, Rinaldi C (2010) Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J Magn Magn Mater 322:2244–2250. doi: 10.1016/j.jmmm.2010.02.01910.1016/j.jmmm.2010.02.019 ↗
9. Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. doi: 10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
10. Dutta RK, Sharma PK, Pandey AC (2010) Design and surface modification of potential luminomagnetic nanocarriers for biomedical applications. J Nanopart Res 12:1211–1219. doi: 10.1007/s11051-009-9801-010.1007/s11051-009-9801-0 ↗
11. Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7:223–225
12. Garcia-Bennett A, Nees M, Fadeel B (2011) In search of the holy grail: folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol 81:976–984. doi: 10.1016/j.bcp.2011.01.02310.1016/j.bcp.2011.01.023 ↗
13. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu JX, Keene DR, Reed CC, Iozzo RV (2007) A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26:368–381. doi: 10.1038/sj.onc.120980310.1038/sj.onc.1209803 ↗
14. Jevnikar Z, Obermajer N, Bogyo M, Kos J (2008) The role of cathepsin X in the migration and invasiveness of T lymphocytes. J Cell Sci 121:2652–2661. doi: 10.1242/jcs.02372110.1242/jcs.023721 ↗
15. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18–26. doi: 10.1016/j.jconrel.2007.03.01210.1016/j.jconrel.2007.03.012 ↗
16. Kralj S, Makovec D, Čampelj S, Drofenik M (2010) Producing ultra-thin silica coatings on iron-oxide nanoparticles to improve their surface reactivity. J Magn Magn Mater 322:1847–1853. doi: 10.1016/j.jmmm.2009.12.03810.1016/j.jmmm.2009.12.038 ↗
17. Kralj S, Drofenik M, Makovec D (2011) Controlled surface functionalization of silica-coated magnetic nanoparticles with terminal amino and carboxyl groups. J Nanopart Res 13:2829–2841. doi: 10.1007/s11051-010-0171-410.1007/s11051-010-0171-4 ↗
18. Kralj S, Rojnik M, Romih R, Jagodič M, Kos J, Makovec D (2012) Effect of surface charge on the cellular uptake of fluorescent magnetic nanoparticles. J Nanopart Res 14:1151–1165. doi: 10.1007/s11051-012-1151-710.1007/s11051-012-1151-7 ↗
19. Laskin JJ, Sandler AB (2004) Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30:1–17. doi: 10.1016/j.ctrv.2003.10.00210.1016/j.ctrv.2003.10.002 ↗
20. Liao C, Sun Q, Liang B, Shen J, Shuai X (2011) Targeting EGFR-overexpressing tumor cells using cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur J Radiol 80:699–705. doi: 10.1016/j.ejrad.2010.08.005
21. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T (2011) Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Delivery Rev 63:24–46. doi: 10.1016/j.addr.2010.05.00610.1016/j.addr.2010.05.006 ↗
22. Meira DD, de Almeida VH, Mororó JS, Nóbrega I, Bardella L, Silva RL, Albano RM, Ferreira CG (2009) Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer 101:782–791. doi: 10.1038/sj.bjc.660521610.1038/sj.bjc.6605216 ↗
23. Pankhurst QA, Connolly J, Jones SK, Dobson J (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D 36:167–181. doi: 10.1088/0022-3727/36/13/20110.1088/0022-3727/36/13/201 ↗
24. Roberts CJ, Williams PM, Davies J, Dawkes AC, Sefton J, Edwards JC, Haymes AG, Bestwick C, Davies MC, Tendler SJB (1995) Real-space differentiation of IgG and IgM antibodies deposited on microtitre wells by scanning force microscopy. Langmuir 11:1822–1826. doi: 10.1021/la00005a06310.1021/la00005a063 ↗
25. Skaat H, Shafir G, Margel S (2011) Acceleration and inhibition of amyloid-β fibril formation by peptide-conjugated fluorescent-maghemite nanoparticles. J Nanopart Res 13:3521. doi: 10.1007/s11051-011-0276-410.1007/s11051-011-0276-4 ↗
26. Stanley SA, Gagner JE, Damanpour S, Yoshida M, Dordick JS, Friedman JM (2012) Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science 336:604–608. doi: 10.1126/science.121675310.1126/science.1216753 ↗
27. Suwa T, Ozawa S, Ueda M, Ando N, Kitajima M (1998) Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 75:626–634. doi: 10.1002/(SICI)1097-0215(19980209)75:4<626:AID-IJC22>3.0.CO;2-510.1002/(SICI)1097-0215(19980209)75:4<626::AID-IJC22>3.0.CO;2-5 ↗
28. Taylor JM, Mitchell WM, Cohen S (1972) Epidermal growth factor. J Biol Chem 247:5928–593410.1016/S0021-9258(19)44847-3 ↗
29. Tiefenauer LX, Kuhne G, Andres RY (1993) Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug Chem 4:347–352. doi: 10.1021/bc00023a00710.1021/bc00023a007 ↗
30. Vigor KL, Kyrtatos PG et al (2010) Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 31:1307–1315. doi: 10.1016/j.biomaterials.2009.10.03610.1016/j.biomaterials.2009.10.036 ↗
31. Wang L, Neoh KG, Kang ET, Shuter B (2011) Multifunctional polyglycerol-grafted Fe3O4@SiO2 nanoparticles for targeting ovarian cancer cells. Biomaterials 32:2166–2173. doi: 10.1016/j.biomaterials.2010.11.04210.1016/j.biomaterials.2010.11.042 ↗
32. Wong HL, Wu XY, Bendayan R (2011) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Delivery Rev 64:686–700. doi: 10.1016/j.addr.2011.10.00710.1016/j.addr.2011.10.007 ↗
33. Wu SH-Y, Tseng C-L, Lin F-H (2010) A newly developed Fe-doped calcium sulfide nanoparticles with magnetic property for cancer hyperthermia. J Nanopart Res 12:1173–1185. doi: 10.1007/s11051-009-9734-710.1007/s11051-009-9734-7 ↗
34. Wuang SC, Neoh KG, Kang ET, Pack DW, Leckband DE (2007) Synthesis and functionalization of polypyrrole-Fe3O4 nanoparticles for applications in biomedicine. J Mater Chem 17:3354–3362. doi: 10.1039/B702983G10.1039/b702983g ↗
35. Yang J, Lim E-K, Lee E-S, Suh J-S, Haam S, Huh Y-M (2010) Magnetoplex based on MnFe2O4 nanocrystals for magnetic labeling and MR imaging of human mesenchymal stem cells. J Nanopart Res 12:1275–1283. doi: 10.1007/s11051-009-9837-110.1007/s11051-009-9837-1 ↗